Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. - Wikidata - awgldk - TriplyDB

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

http://www.wikidata.org/entity/Q37351043

about

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma Current challenges and novel treatment strategies in double hit lymphomas MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management Biology of double-hit B-cell lymphomas Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Primary bladder lymphoma, diffuse large B-cell type: Case report and literature review of 26 cases.Nature and importance of follicular lymphoma precursors.Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.Transformation of follicular lymphoma The essential role of evasion from cell death in cancer.Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.The histological classification of diffuse large B-cell lymphomas Aggressive B-cell lymphomas: how many categories do we need?Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.Grey zone lymphomas: lymphomas with intermediate features.Management of Patients with MYC-Altered Lymphomas.Genetic lesions in diffuse large B-cell lymphomas MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma Cell of origin of transformed follicular lymphoma Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification Pathogenesis of follicular lymphoma Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

P2860

Q24294856-B8A34798-C713-448C-A845-39E3E5B5F77F Q26770385-3D54ABA1-04E2-4CB5-9A77-B5463C8FB104 Q26785379-841F483E-2150-4CD2-AD90-528DCB60E91E Q26825581-F5A99F5D-E686-414B-A99E-0283A5FFE053 Q27304386-C23FD1A4-806B-4EE7-90CE-696D65EADB0F Q28256567-C4F67DA5-FB92-4EA2-A31E-B4981926DA8A Q30406180-4CCF915E-6B14-475B-B9FE-D040767776C1 Q33558757-9900FCBC-1038-4095-8F14-A78D9A19128E Q33560762-2555DAF9-5D5A-4496-BF2B-55253FCEC19A Q33670880-4EAED63B-41CC-432E-8795-8C86B8305967 Q33688416-CA88E7C8-5E8C-482B-AF05-FB6004AA721B Q33846801-5B710B53-0B51-4126-B87F-6952CA96D34A Q33909737-4B04FB38-2FD9-4336-B17D-A1437F629322 Q33980435-76CBC903-73AA-4CF2-A852-79BC7D5B1D45 Q34023761-D07D7D50-B814-4B09-A2BB-0CB18F49B78E Q34314178-7C1CA29E-5893-4AFA-A2AA-13B9BADEA730 Q34335894-E391635B-7A68-410E-BDCE-D16DACCF1496 Q34775356-FAB2BCA9-CB17-4D6C-BE13-340DC56CE969 Q34882773-3FFE19CA-6328-4C3E-BE43-78594B8CCB45 Q34918948-F02BC167-4DD9-40AB-A649-53AD0E4C7ED8 Q35030096-1C54EB7E-1E75-45E1-B176-D14969174591 Q35038729-067568C2-02FE-43E3-8F35-FDD99A4B86ED Q35083049-252BF23F-B617-4109-9495-B1ADDF963149 Q35128216-C9C87991-997E-4778-891E-601EA2EF79F1 Q35153156-C5703CD5-9741-4787-859C-936341890762 Q35218051-316B9D29-0144-4849-96FF-AB3660B06DD2 Q35527893-6A9BED98-41E3-4FE2-AA02-3781671B5CEF Q35797583-8E9CF2A9-C17E-4435-8ADA-A3CD7DADA649 Q35881523-CB0C485E-85FF-44B4-9FAB-362509C03D80 Q35882774-F7A445FD-6AFA-4107-8998-EBCB8C8D38F0 Q35960027-0C13AADF-6B67-4C10-93A6-2148B31BB2EF Q35974341-9FC70AE8-A949-4B2B-B7E9-9566A550AD74 Q36210875-A18BB536-55F3-4FD3-9D06-B38CC09D9389 Q36225164-258E5CBB-2590-4DF0-A292-BA04BAC195D5 Q36267666-C535F199-C750-402B-9F28-0171FD3ECAD7 Q36280547-B38D0D21-428D-417B-98BE-27CC0A6B3410 Q36290288-DDD37FE3-70CB-4536-B238-E0C36C311202 Q36467468-64870173-06E7-4B23-B44F-A8A5FE23C5A0 Q36579119-E00DD738-854A-496D-AD55-C0EA17273D55 Q36596874-B07B78BE-1436-436C-B8BA-4DB2AD9BFC5D

P2860

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

http://www.wikidata.org/entity/Q37351043

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@en

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@nl

type

label

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@en

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@nl

prefLabel

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@en

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@nl

P1433

Q37351043-9BE43C64-542B-4B18-AFCD-948A897262A2

P1476

Q37351043-4A8EEADA-7E35-40AB-83EB-28097DEA74A0

P2093

Q37351043-1BF66787-D7BA-43FB-A9BE-1241D7F2A98D

Q37351043-29D07080-E07C-42C4-9286-E85817C4C880

Q37351043-2EA16021-72C9-4205-950B-C7E94293F945

Q37351043-3D9F024A-4CEC-425F-A073-024B1DC77B8B

Q37351043-5C9225E1-E598-493E-B78D-C31071FC59A6

Q37351043-8D9D2138-F8CE-4662-93B5-FBC9E20DC711

Q37351043-9974DD72-90AB-43E5-BAEE-9E25CB7A4769

Q37351043-F2F7036F-54A3-4C23-A0E4-92577205BB0C

Q37351043-F8CD601D-7552-46AD-BCAD-EC8147E22BFA

Q37351043-FCD8484F-C6F6-4AA2-BC12-06C0E68B7E9C

P2860

Q37351043-082ECAB1-549D-4E59-B222-CE4633391A3B

Q37351043-10C27469-AB1A-49C6-B3FB-F9FC70B91A82

Q37351043-1C4BF183-F8C9-4064-B7BA-09CB62970F70

Q37351043-325C13E5-F02C-4153-92E1-C1ECDF808890

Q37351043-426B876B-D4C5-4C2E-9594-D69FFC5397AD

Q37351043-42EE02A6-A056-49C9-A3CA-143D537CB944

Q37351043-5E438828-5946-457C-8F34-E5C74EE1232D

Q37351043-7982CD1E-F017-4402-9305-AC6503CBDE88

Q37351043-82AD05A8-7EB8-4777-8428-F78892EB86BB

Q37351043-85E5BD0B-B4FE-41F1-BED6-856C076DC293

P304

Q37351043-3FF6C5C4-5A24-4C58-903A-49B5EA500894

P31

Q37351043-54E11B83-D551-4616-ACF3-F23198CD9792

P356

Q37351043-487A080F-7C24-47D5-8A34-021FE45FC166

P407

Q37351043-96E1EC4C-31A0-4A20-BF19-3D057D76642A

P433

Q37351043-6AE4A172-27A0-45E5-85DA-A65172E6991C

P478

Q37351043-2784220A-EB05-414E-97A0-F9D30963213B

P50

Q37351043-23D310CF-4A32-46EB-9661-397FE2457F4E

Q37351043-2D0A405D-FC33-45F1-9E75-31ED31257B8C

Q37351043-D083A159-0D30-455A-A02C-2FC28A9A83BD

P577

Q37351043-6266DB61-3F84-49B3-AEE5-31DBA3B01297

P5875

Q37351043-EB5D23A0-73B6-4930-9D8E-ACA87E2BE865

P698

Q37351043-1370BA54-CB51-4FA0-8833-701FB20C93A5

P932

Q37351043-BC43FC61-43DF-4E2E-8AE4-2DB8A29ABDFA

P356

BLOOD-2009-03-212191

P1433

P1476

Lymphomas with concurrent BCL2 ...... tors associated with survival.

@en

P2093

Christian Steidl

http://www.w3.org/2001/XMLSchema#string

Douglas E Horsman

http://www.w3.org/2001/XMLSchema#string

John Kuruvilla

http://www.w3.org/2001/XMLSchema#string

Kerry J Savage

http://www.w3.org/2001/XMLSchema#string

Martin J S Dyer

http://www.w3.org/2001/XMLSchema#string

Nathalie A Johnson

http://www.w3.org/2001/XMLSchema#string

Olga Ludkovski

http://www.w3.org/2001/XMLSchema#string

Richard Klasa

http://www.w3.org/2001/XMLSchema#string

Ryan Woods

http://www.w3.org/2001/XMLSchema#string

Susana Ben-Neriah

http://www.w3.org/2001/XMLSchema#string

P2860

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.

Phosphorylation of Bcl2 and regulation of apoptosis.

Bcl2's flexible loop domain regulates p53 binding and survival

Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.

De novo acute B-cell leukemia with translocation t(14;18): an entity with a poor prognosis.

Pax5: the guardian of B cell identity and function.

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

The c-myc promoter: still MysterY and challenge.

P304

2273-2279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-03-212191

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M Connors

Randy D Gascoyne

P577

2009-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26665867

http://www.w3.org/2001/XMLSchema#string

P698

19597184

http://www.w3.org/2001/XMLSchema#string

P932

2745846

http://www.w3.org/2001/XMLSchema#string